{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:17:34Z","timestamp":1787887054038,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04426-5","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:55:36Z","timestamp":1781844936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interferon-induced interstitial lung disease: a rare adverse effect induced by pegylated interferon-alpha in a patient with chronic hepatitis B-case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Haoyue","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"2","key":"4426_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5578\/tt.35288","volume":"65","author":"O Okutan","year":"2017","unstructured":"Okutan O, Ayten \u00d6. Hepatitis C and pulmonary fibrosis. Tuberk Toraks. 2017;65(2):131\u20137.","journal-title":"Tuberk Toraks"},{"key":"4426_CR2","doi-asserted-by":"crossref","unstructured":"Ji FP. Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol. 2010;16(35):4394\u20139.","DOI":"10.3748\/wjg.v16.i35.4394"},{"key":"4426_CR3","doi-asserted-by":"crossref","unstructured":"Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24(1):38\u201347.","DOI":"10.1016\/S0168-8278(96)80184-X"},{"key":"4426_CR4","doi-asserted-by":"crossref","unstructured":"Midturi J, Sierra-Hoffman M , Hurley D, Winn R, Beissner R, Carpenter J. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature. Clin Infect Dis. 2004;39(11):1724\u20139.","DOI":"10.1086\/425746"},{"issue":"08","key":"4426_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5414\/CP204504","volume":"62","author":"M Shi","year":"2024","unstructured":"Shi M, Wang S, Ren Y, et al. Pegylated-interferon alpha (PEG-IFN\u03b1)-induced interstitial lung disease in a patient with chronic hepatitis B: a case report and literature review. Int J Clin Pharmacol Ther. 2024;62(08):386\u201394.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4426_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2025.e02191","author":"B Tian","year":"2025","unstructured":"Tian B, Wang P, Shan C, et al. Organizing pneumonia in a patient following treatment of chronic hepatitis B with pegylated interferon alfa-2b: a case report. IDCases. 2025. https:\/\/doi.org\/10.1016\/j.idcr.2025.e02191.","journal-title":"IDCases"},{"key":"4426_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02776-2021","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.02776-2021.","journal-title":"Eur Respir J"},{"key":"4426_CR8","doi-asserted-by":"crossref","unstructured":"Yousem SA, Dacic S . Idiopathic bronchiolocentric interstitial pneumonia. Mod Pathol. 2002;15(11):1148\u201353.","DOI":"10.1097\/01.MP.0000037309.04985.B4"},{"key":"4426_CR9","doi-asserted-by":"crossref","unstructured":"Goeckenjan G. Respiratorische Bronchiolitis mit interstitieller Lungenerkrankung (RB-ILD). Pneumologie. 2003;57(5):278\u201387.","DOI":"10.1055\/s-2003-39368-2"},{"issue":"4","key":"4426_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000079633","volume":"71","author":"P Camus","year":"2004","unstructured":"Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301\u201326.","journal-title":"Respiration"},{"key":"4426_CR11","doi-asserted-by":"crossref","unstructured":"Matsuno O . Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39.","DOI":"10.1186\/1465-9921-13-39"},{"issue":"17","key":"4426_CR12","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","volume":"20","author":"JM Kirkwood","year":"2002","unstructured":"Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20(17):3703\u201318.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4426_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1378\/chest.105.3.939","volume":"105","author":"K Chin","year":"1994","unstructured":"Chin K, Tabota C, Kuno K, et al. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest. 1994;105(3):939\u201341.","journal-title":"Chest"},{"issue":"9","key":"4426_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1872-034X.2011.00837.x","volume":"41","author":"Y Ichikawa-Yamada","year":"2011","unstructured":"Ichikawa-Yamada Y, Joshita S, Tsukahara Y, et al. Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy. Hepatol Res. 2011;41(9):904\u20139.","journal-title":"Hepatol Res"},{"key":"4426_CR15","doi-asserted-by":"crossref","unstructured":"Ji F, Li Z , Xue H, Liu L, Deng H. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection. South Med J. 2011;104(2):140\u20132.","DOI":"10.1097\/SMJ.0b013e318206f8e3"},{"key":"4426_CR16","unstructured":"Qu C, Zheng Z , Liu W, Jiao J, Zhu J. A case of chronic hepatitis C patient of myocardial ischemia accompanied with interstitial pneumonia induced by pegylated interferon alpha-2a. Int J Clin Exp Pathol. 2014;7(8):5232\u20135."},{"key":"4426_CR17","unstructured":"Botnaru V, Munteanu O, Rusu D. Interstitial pneumonitis after treatment for hepatitis C virus infection. Pneumologia. 2015;64(1):46\u201350."},{"key":"4426_CR18","first-page":"1","volume":"2015","author":"A Chopra","year":"2015","unstructured":"Chopra A, Marak C, Alappan N, et al. Organizing pneumonia associated with pegylated interferon\u03b1and ribavirin therapy. Case Rep Pulmonol. 2015;2015:1\u20134.","journal-title":"Case Rep Pulmonol"},{"issue":"15","key":"4426_CR19","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2169\/internalmedicine.46.0150","volume":"46","author":"Y Arase","year":"2007","unstructured":"Arase Y, Ikeda K, Suzuki Y, et al. Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. Intern Med. 2007;46(15):1155\u201360.","journal-title":"Intern Med"},{"key":"4426_CR20","doi-asserted-by":"crossref","unstructured":"Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, Sakamoto N, Matsuoka Y, Kubota H, Mine M, Mukae H, Nagata K, Kohno S. Serum heat shock protein 47 levels in patients with drug-induced lung disease. Respir Res. 2013;14(1):133.","DOI":"10.1186\/1465-9921-14-133"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04426-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:26:05Z","timestamp":1787883965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04426-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4426"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04426-5","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient was treated ethically under the Declaration of Helsinki. All procedures performed in studies involving human participants were in accordance with the ethical standards of the 958th Army Hospital of the Chinese People\u2019s Liberation Army. Written informed consent was obtained from the patient.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"380"}}